PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 52 people, planned
- Started
- 20 May 2024
- Expected to end
- 20 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Perampanel
- Placebo
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥18 years old
- Non-traumatic, out-of-hospital cardiac arrest
- Comatose on admission - defined as not following commands
- Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
- Admission to the intensive care unit at Zuckerberg San Francisco General Hospital
Who cannot take part
- Acute cerebral hemorrhage or infarction
- Severe liver impairment with liver function tests five times above the upper limit of normal
- Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest
- Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
- Pregnancy
- Prisoner
This trial is currently available in United States.
- Zuckerberg San Francisco General HospitalSan Francisco, United StatesContact: Edilberto Amorim, MDTaking people
About the trial
What the trial wants to find out
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
The 2 groups in the trial
- PerampanelExisting treatment, for comparison
Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)
- PlaceboPlacebo, for comparison
Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 July 2026